Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2714-2724

  Winter, Dorian ^a,c   Fiebiger, Edda ^c,d   Meraner, Paul ^a   Auer, Herbert ^e   Brna, Christine ^a   Strohal, Robert ^a   Trautinger, Franz ^a   Knobler, Robert ^a   Fischer, Gottfried F ^b   Stingl, Georg ^a   Maurer, Dieter ^a,c  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d HARVARD MEDICAL SCHOOL   (United States)

^e RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT RECEPTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ARTICLE; BINDING AFFINITY; CELL LINE; CELL STIMULATION; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MOLECULAR RECOGNITION; PROTEIN EXPRESSION; VACCINATION;

EID: 0042429217     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2714     Document Type: Article

References (39)

1. Heald, P. W., and R. L. Edelson. 1999. Cutaneous T cell lymphomas. In Fitzpatrick's Dermatology in General Medecine, Vol. 1. I. M. Freedberg, A. Z. Eisen, K. Wolff, K. F. Austen, L. A. Goldsmith, S. I. Katz, and T. B. Fitzpatrick, eds. McGraw-Hill, New York, p. 1227.
2. Murphy, M., D. Fullen, and J. A. Carlson. 2002. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am. J. Dermatopathol. 24:6.
3. Willemze, R., H. Kerl, W. Sterry, E. Berti, L. Cerroni, S. Chimenti, J. L. Diaz-Perez, M. L. Geerts, M. Goos, R. Knobler, et al. 1997. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354.
4. Edelson, R., C. Berger, F. Gasparro, B. Jegasothy, P. Heald, B. Wintroub, E. Vonderheid, R. Knobler, K. Wolff, G. Plewig, et al. 1987. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N. Engl. J. Med. 316:297.
5. Berger, C. L., N. Wang, I. Christensen, J. Longley, P. Heald, and R. L. Edelson. 1996. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J. Invest. Dermatol. 107:392.
6. +. T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91:4331.
7. Seo, N., Y. Tokura, K. Matsumoto, F. Furukawa, and M. Takigawa. 1998. Tumor-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-γ (IFN-γ) and IL-12 and fluctuations in association with disease activity. Clin. Exp. Immunol. 112:403.
8. Eichmüller, S., D. Usener, R. Dummer, A. Stein, D. Thiel, and D. Schadendorf. 2001. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc. Natl. Acad. Sci. USA 98:629.
9. Linnemann, T., S. Tumenjargal, S. Gellrich, K. Wiesmuller, K. Kaltoft, W. Sterry, and P. Walden. 2001. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur. J. Immunol. 31:156.
10. Berger, C. L., B. J. Longley, S. Imaeda, I. Christensen, P. Heald, and R. L. Edelson. 1998. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int. J. Cancer 76:304.
11. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 89:3129.
12. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
13. Timmerman, J. M., D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517.
14. Trojan, A., J. L. Schultze, M. Witzens, R. H. Vonderheide, M. Ladetto, J. W. Donovan, and J. G. Gribben. 2000. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6:667.
15. Syrengelas, A. D., and R. Levy. 1999. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol. 162:4790.
16. Fan, G. C., and R. R. Singh. 2002. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J. Exp. Med. 196:731.
17. Zang, Y. C., J. Hong, V. M. Rivera, J. Killian, and J. Z. Zhang. 2000. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J. Immunol. 164:4011.
18. + T cells. Immunity 2:177.
19. + T cells expressing Vβ8 TCR: a role of the Qa-1 molecule. Immunity 2:185.
20. Okada, C. Y., C. P. Wong, D. W. Denney, and R. Levy. 1997. TCR vaccines for active immunotherapy of T cell malignancies. J. Immunol. 159:5516.
21. + T cell response. J. Immunol. 162:2251.
22. Wong, C. P., and R. Levy. 2000. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. Cancer Res. 60:2689.
23. Yu, H., G. Kaung, S. Kobayashi, and R. R. Kopito. 1997. Cytosolic degradation of T-cell receptor a chains by the proteasome. J. Biol. Chem. 272:20800.
24. Huppa, J. B., and H. L. Ploegh. 1997. The α chain of the T cell antigen receptor is degraded in the cytosol. Immunity 7:113.
25. Liu, H., M. Rhodes, D. L. Wiest, and D. A. Vignali. 2000. On the dynamics of TCR:CD3 complex cell surface expression and down-modulation. Immunity 13:665.
26. + peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163:3250.
27. + precursor cells develop into Langerhans cells in a TGF-β1-dependent manner. J. Immunol. 163:4869.
28. Stuber, G., G. H. Leder, W. T. Storkus, M. T. Lotze, S. Modrow, L. Szekely, H. Wolf, E. Klein, K. Karre, and G. Klein. 1994. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol. 24:765.
29. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 21:235.
30. Strohal, R., C. Brna, U. Mossbacher, G. Fischer, H. Pehamberger, and G. Stingl. 1998. First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites. J. Invest. Dermatol. 111:1085.
31. Bremers, A. J., S. H. van der Burg, P. J. Kuppen, W. M. Kast, C. J. van de Velde, and C. J. Melief. 1995. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. J. Immunother. Emphasis Tumor Immunol. 18:77.
32. Van der Burg, S. H., E. Ras, J. W. Drijfhout, W. E. Benckhuijsen, A. J. Bremers, C. J. Melief, and W. M. Kast. 1995. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells: identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum. Immunol. 44:189.
33. Fiebiger, E., P. Meraner, E. Weber, I. F. Fang, G. Stingl, H. Ploegh, and D. Maurer. 2001. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J. Exp. Med. 193:881.
34. Blomberg, K., C. Granberg, I. Hemmila, and T. Lovgren. 1986. Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J. Immunol. Methods 86:225.
35. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213.
36. Nussbaum, A. K., C. Kuttler, K. P. Hadeler, H. G. Rammensee, and H. Schild. 2001. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53:87.
37. Bendandi, M., C. D. Gocke, C. B. Kobrin, F. A. Benko, L. A. Sternas, R. Pennington, T. M. Watson, C. W. Reynolds, B. L. Gause, P. L. Duffey, et al. 1999. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5:1171.
38. Madakamutil, L. T., I. Maricic, E. Sercarz, and V. Kumar. 2003. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 170:2985.
39. Chadburn, A., G. Inghirami, and D. M. Knowles. 1992. T-cell activation-associated antigen expression by neoplastic T-cells. Hematol. Pathol. 6:131.